Clinical trial
Study to Evaluate Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients
NCT02228421
Drugs and interventions used in this trial
0 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No interventions are currently published for this study in CureCurrent. View the original registry record below.
Study at a glance
Registry-backedStudy to Evaluate Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients
Design: OBSERVATIONAL · Status: TERMINATED · Phase: Not specified
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Non-small Cell Lung Cancer Metastaticunresolved
Interventions
Sponsors & collaborators
PeriPharmlead sponsor
Personalized Medicine Partnership for Cancercollaborator
Jewish General Hospitalcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02228421 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.